Celgene Corporation (CELG) Shares Sold by Bainco International Investors

Bainco International Investors cut its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 2.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 70,226 shares of the biopharmaceutical company’s stock after selling 1,441 shares during the quarter. Celgene Corporation accounts for about 1.4% of Bainco International Investors’ portfolio, making the stock its 22nd largest holding. Bainco International Investors’ holdings in Celgene Corporation were worth $9,120,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of CELG. Peddock Capital Advisors LLC raised its position in Celgene Corporation by 5.2% during the 1st quarter. Peddock Capital Advisors LLC now owns 13,835 shares of the biopharmaceutical company’s stock worth $1,721,000 after buying an additional 684 shares during the last quarter. Highland Private Wealth Management grew its stake in shares of Celgene Corporation by 7.0% during the 1st quarter. Highland Private Wealth Management now owns 2,541 shares of the biopharmaceutical company’s stock worth $316,000 after purchasing an additional 167 shares during the period. Beach Investment Counsel Inc. PA grew its stake in shares of Celgene Corporation by 5.2% during the 1st quarter. Beach Investment Counsel Inc. PA now owns 67,266 shares of the biopharmaceutical company’s stock worth $8,370,000 after purchasing an additional 3,353 shares during the period. Mosaic Family Wealth LLC grew its stake in shares of Celgene Corporation by 12.9% during the 1st quarter. Mosaic Family Wealth LLC now owns 1,642 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 188 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Celgene Corporation by 29.9% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 57,708 shares of the biopharmaceutical company’s stock worth $7,181,000 after purchasing an additional 13,270 shares during the period. 79.16% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Celgene Corporation (CELG) Shares Sold by Bainco International Investors” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.com-unik.info/2017/11/18/celgene-corporation-celg-shares-sold-by-bainco-international-investors.html.

In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of Celgene Corporation stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,227 shares of company stock valued at $2,843,956. 0.95% of the stock is currently owned by corporate insiders.

Shares of Celgene Corporation (NASDAQ:CELG) opened at $104.10 on Friday. The stock has a market cap of $81,370.00, a PE ratio of 15.45, a P/E/G ratio of 0.76 and a beta of 1.79. Celgene Corporation has a fifty-two week low of $94.55 and a fifty-two week high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. Celgene Corporation’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.58 EPS. equities analysts predict that Celgene Corporation will post 6.67 earnings per share for the current year.

A number of equities research analysts have recently commented on the stock. Morgan Stanley cut shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective on the stock. in a research note on Thursday, October 5th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $173.00 price objective on shares of Celgene Corporation in a research note on Thursday, October 5th. Robert W. Baird reaffirmed a “buy” rating and set a $162.00 price objective on shares of Celgene Corporation in a research note on Thursday, September 21st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $162.00 price objective on shares of Celgene Corporation in a research note on Tuesday, September 26th. Finally, Bank of America Corporation reaffirmed a “buy” rating on shares of Celgene Corporation in a research note on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $139.87.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit